

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICATION NO.: 10/627,331

ATTY. DOCKET NO.: C1039.70078US00

FILING DATE: July 25, 2003

CONFIRMATION NO.: 4362

APPLICANT: Krieg et al.

GROUP ART UNIT: 1648

EXAMINER: Emily M. Le

Sheet

1

of

12

DEC 17 2007

U.S. PATENT DOCUMENTS

| Examiner's Initials # | Cite No. | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication or Issue of Cited Document MM-DD-YYYY |
|--------------------------|-------------|----------------------|--------------|--|---|
| | | Number | Kind Code | | |
| | | 5,567,604 | | Rando et al. | 10-22-1996 |
| | | 5,576,302 | | Cook et al. | 11-19-1996 |
| | | 5,658,891 | | Draper et al. | 08-19-1997 |
| | | 5,663,153 | | Hutcherson et al. | 09-02-1997 |
| | | 5,723,335 | | Hutcherson et al. | 03-03-1998 |
| | | 5,728,518 | | Carmichael | 03-17-1998 |
| | | 5,985,662 | | Anderson et al. | 11-16-1999 |
| | | 6,221,882 | B1 | Macfarlane | 04-24-2001 |
| | | 6,399,630 | B1 | Macfarlane | 06-04-2002 |
| | | 6,479,504 | B1 | Macfarlane et al. | 11-12-2002 |
| | | 6,503,533 | B1 | Korba et al. | 01-07-2003 |
| | | 6,521,637 | B2 | Macfarlane | 02-18-2003 |
| | | 6,727,230 | B1 | Hutcherson et al. | 04-27-2004 |
| | | 6,821,957 | B1 | Krieg et al. | 11-23-2004 |
| | | 6,943,240 | B2 | Bauer et al. | 09-13-2005 |
| | | 6,949,520 | B1 | Hartmann et al. | 09-27-2005 |
| | | 7,001,890 | B1 | Wagner et al. | 02-21-2006 |
| | | 7,223,741 | B2 | Krieg | 05-29-2007 |
| | | 7,271,156 | B2 | Krieg et al. | 07-18-2007 |
| | | 2001-0044416 | A1 | McCluskie et al. | 11-22-2001 |
| | | 2002-0086839 | A1 | Raz et al. | 07-04-2002 |
| | | 2002-0091097 | A1 | Bratzler et al. | 07-11-2002 |
| | | 2002-0164341 | A1 | Davis et al. | 11-07-2002 |
| | | 2002-0165178 | A1 | Schetter et al | 11-07-2002 |
| | | 2002-0198165 | A1 | Bratzler et al. | 12-26-2002 |
| | | 2003-0026782 | A1 | Krieg | 02-02-2003 |
| | | 2003-0026801 | A1 | Weiner et al. | 02-06-2003 |
| | | 2003-0050268 | A1 | Krieg et al. | 03-13-2003 |
| | | 2003-0055014 | A1 | Bratzler | 03-20-2003 |
| | | 2003-0091599 | A1 | Davis et al. | 05-15-2003 |
| | | 2003-0100527 | A1 | Krieg et al. | 05-29-2003 |
| | | 2003-0139364 | A1 | Krieg et al. | 07-24-2003 |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | | | |
|--|---|----|----|-----------------------------|--|-----------------------------------|--|
| FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICATION NO.: 10/627,331 | | ATTY. DOCKET NO.: C1039.70078US00 | |
| | | | | FILING DATE: July 25, 2003 | | CONFIRMATION NO.: 4362 | |
| | | | | APPLICANT: Krieg et al. | | | |
| | | | | GROUP ART UNIT: 1648 | | EXAMINER: Emily M. Le | |
| Sheet | 2 | of | 12 | | | | |

| | | | | | |
|--|--|--------------|----|-----------------|------------|
| | | 2003-0148316 | A1 | Lipford et al. | 08-07-2003 |
| | | 2003-0148976 | A1 | Krieg et al. | 08-07-2003 |
| | | 2003-0166001 | A1 | Lipford | 09-04-2003 |
| | | 2003-0181406 | A1 | Schetter et al. | 09-25-2003 |
| | | 2003-0191079 | A1 | Krieg et al. | 10-09-2003 |
| | | 2003-0224010 | A1 | Davis et al. | 12-04-2003 |
| | | 2003-0232074 | A1 | Lipford et al. | 12-18-2003 |
| | | 2003-0232780 | A1 | Carson et al. | 12-18-2003 |
| | | 2003-0232856 | A1 | Macfarlane | 12-18-2003 |
| | | 2004-0006010 | A1 | Carson et al. | 01-08-2004 |
| | | 2004-0006034 | A1 | Raz et al. | 01-08-2004 |
| | | 2004-0009949 | A1 | Krieg | 01-15-2004 |
| | | 2004-0030118 | A1 | Wagner et al. | 02-12-2004 |
| | | 2004-0053880 | A1 | Krieg | 03-18-2004 |
| | | 2004-0067902 | A9 | Bratzler et al. | 04-08-2004 |
| | | 2004-0067905 | A1 | Krieg | 04-08-2004 |
| | | 2004-0087534 | A1 | Krieg et al. | 05-06-2004 |
| | | 2004-0087538 | A1 | Krieg et al. | 05-06-2004 |
| | | 2004-0092468 | A1 | Schwartz et al. | 05-13-2004 |
| | | 2004-0092472 | A1 | Krieg | 05-13-2004 |
| | | 2004-0106568 | A1 | Krieg et al. | 06-03-2004 |
| | | 2004-0131628 | A1 | Bratzler et al. | 07-08-2004 |
| | | 2004-0132685 | A1 | Krieg et al. | 07-08-2004 |
| | | 2004-0142469 | A1 | Krieg et al. | 07-22-2004 |
| | | 2004-0143112 | A1 | Krieg et al. | 07-22-2004 |
| | | 2004-0147468 | A1 | Krieg et al. | 07-29-2004 |
| | | 2004-0152649 | A1 | Krieg | 08-05-2004 |
| | | 2004-0152656 | A1 | Krieg et al. | 08-05-2004 |
| | | 2004-0152657 | A1 | Krieg et al. | 08-05-2004 |
| | | 2004-0162258 | A1 | Krieg et al. | 08-19-2004 |
| | | 2004-0162262 | A1 | Krieg et al. | 08-19-2004 |
| | | 2004-0167089 | A1 | Krieg et al. | 08-26-2004 |
| | | 2004-0171150 | A1 | Krieg et al. | 09-02-2004 |
| | | 2004-0171571 | A1 | Krieg et al. | 09-02-2004 |
| | | 2004-0181045 | A1 | Krieg et al. | 09-16-2004 |
| | | 2004-0198680 | A1 | Krieg | 10-07-2004 |

| | |
|-----------|------------------|
| EXAMINER: | DATE CONSIDERED: |
|-----------|------------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | | | | | |
|--|---|----|----|-----------------------------|--|-----------------------------------|--|--|--|
| FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICATION NO.: 10/627,331 | | ATTY. DOCKET NO.: C1039.70078US00 | | | |
| | | | | FILING DATE: July 25, 2003 | | CONFIRMATION NO.: 4362 | | | |
| | | | | APPLICANT: Krieg et al. | | | | | |
| | | | | GROUP ART UNIT: 1648 | | EXAMINER: Emily M. Le | | | |
| Sheet | 3 | of | 12 | | | | | | |

| | | | | | |
|--|--|--------------|----|-------------------|------------|
| | | 2004-0198688 | A1 | Krieg et al. | 10-07-2004 |
| | | 2004-0229835 | A1 | Krieg et al. | 11-18-2004 |
| | | 2004-0234512 | A1 | Wagner et al. | 11-25-2004 |
| | | 2004-0235770 | A1 | Davis et al. | 11-25-2004 |
| | | 2004-0235774 | A1 | Bratzler et al. | 11-25-2004 |
| | | 2004-0235777 | A1 | Wagner et al. | 11-25-2004 |
| | | 2004-0235778 | A1 | Wagner et al. | 11-25-2004 |
| | | 2004-0266719 | A1 | McCluskie et al. | 12-30-2004 |
| | | 2005-0004061 | A1 | Krieg et al. | 01-06-2005 |
| | | 2005-0004062 | A1 | Krieg et al. | 01-06-2005 |
| | | 2005-0009774 | A1 | Krieg et al. | 01-13-2005 |
| | | 2005-0032734 | A1 | Davis et al. | 02-10-2005 |
| | | 2005-0032736 | A1 | Krieg et al. | 02-10-2005 |
| | | 2005-0037403 | A1 | Krieg et al. | 02-17-2005 |
| | | 2005-0037985 | A1 | Krieg et al. | 02-17-2005 |
| | | 2005-0043529 | A1 | Davis et al. | 02-24-2005 |
| | | 2005-0049215 | A1 | Krieg et al. | 03-03-2005 |
| | | 2005-0049216 | A1 | Krieg et al. | 03-03-2005 |
| | | 2005-0054601 | A1 | Wagner et al. | 03-10-2005 |
| | | 2005-0054602 | A1 | Krieg et al. | 03-10-2005 |
| | | 2005-0059619 | A1 | Krieg et al. | 03-17-2005 |
| | | 2005-0059625 | A1 | Krieg et al. | 03-17-2005 |
| | | 2005-0070491 | A1 | Krieg et al. | 03-31-2005 |
| | | 2005-0075302 | A1 | Hutcherson et al. | 04-07-2005 |
| | | 2005-0100983 | A1 | Bauer et al. | 05-12-2005 |
| | | 2005-0101554 | A1 | Krieg et al. | 05-12-2005 |
| | | 2005-0101557 | A1 | Krieg et al. | 05-12-2005 |
| | | 2005-0119273 | A1 | Lipford et al. | 06-02-2005 |
| | | 2005-0123523 | A1 | Krieg et al. | 06-09-2005 |
| | | 2005-0130911 | A1 | Uhlmann et al. | 06-16-2005 |
| | | 2005-0148537 | A1 | Krieg et al. | 07-07-2005 |
| | | 2005-0169888 | A1 | Hartman et al. | 08-04-2005 |
| | | 2005-0171047 | A1 | Krieg et al. | 08-04-2005 |
| | | 2005-0181422 | A1 | Bauer et al. | 08-18-2005 |
| | | 2005-0182017 | A1 | Krieg | 08-18-2005 |
| | | 2005-0197314 | A1 | Krieg et al. | 09-08-2005 |

| | |
|-----------|------------------|
| EXAMINER: | DATE CONSIDERED: |
|-----------|------------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | | | | | |
|---|---|----|----|-----------------------------|--|-----------------------------------|--|--|--|
| FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICATION NO.: 10/627,331 | | ATTY. DOCKET NO.: C1039.70078US00 | | | |
| | | | | FILING DATE: July 25, 2003 | | CONFIRMATION NO.: 4362 | | | |
| | | | | APPLICANT: Krieg et al. | | | | | |
| | | | | GROUP ART UNIT: 1648 | | EXAMINER: Emily M. Le | | | |
| Sheet | 4 | of | 12 | | | | | | |

| | | | | | |
|--|--|--------------|----|------------------|------------|
| | | 2005-0215501 | A1 | Lipford et al. | 09-29-2005 |
| | | 2005-0233995 | A1 | Krieg et al. | 10-20-2005 |
| | | 2005-0233999 | A1 | Krieg et al. | 10-20-2005 |
| | | 2005-0239732 | A1 | Krieg et al. | 10-27-2005 |
| | | 2005-0239733 | A1 | Jurk et al. | 10-27-2005 |
| | | 2005-0239734 | A1 | Uhlmann et al. | 10-27-2005 |
| | | 2005-0239736 | A1 | Krieg et al. | 10-27-2005 |
| | | 2005-0244379 | A1 | Krieg et al. | 11-03-2005 |
| | | 2005-0244380 | A1 | Krieg et al. | 11-03-2005 |
| | | 2005-0245477 | A1 | Krieg et al. | 11-03-2005 |
| | | 2005-0250726 | A1 | Krieg et al. | 11-10-2005 |
| | | 2005-0256073 | A1 | Lipford et al. | 11-17-2005 |
| | | 2005-0267064 | A1 | Krieg et al. | 12-01-2005 |
| | | 2005-0277604 | A1 | Krieg et al. | 12-15-2005 |
| | | 2005-0277609 | A1 | Krieg et al. | 12-15-2005 |
| | | 2006-0003955 | A1 | Krieg et al. | 01-05-2006 |
| | | 2006-0003962 | A1 | Ahluwalia et al. | 01-05-2006 |
| | | 2006-0019916 | A1 | Krieg et al. | 01-26-2006 |
| | | 2006-0019923 | A1 | Davis et al. | 01-26-2006 |
| | | 2006-0058251 | A1 | Krieg et al. | 03-16-2006 |
| | | 2006-0089326 | A1 | Krieg et al. | 04-27-2006 |
| | | 2006-0094683 | A1 | Krieg et al. | 05-04-2006 |
| | | 2006-0140875 | A1 | Krieg et al. | 06-29-2006 |
| | | 2006-0154890 | A1 | Bratzler et al. | 07-13-2006 |
| | | 2006-0172966 | A1 | Lipford et al. | 08-03-2006 |
| | | 2006-0188913 | A1 | Krieg et al. | 08-24-2006 |
| | | 2006-0211639 | A1 | Bratzler et al. | 09-21-2006 |
| | | 2006-0211644 | A1 | Krieg et al. | 09-21-2006 |
| | | 2006-0229271 | A1 | Krieg et al. | 10-12-2006 |
| | | 2006-0241076 | A1 | Uhlmann et al. | 10-26-2006 |
| | | 2006-0246035 | A1 | Ahluwalia et al. | 11-02-2006 |
| | | 2006-0286070 | A1 | Hartmann et al. | 12-21-2006 |
| | | 2006-0287263 | A1 | Davis et al. | 12-21-2006 |
| | | 2007-0009482 | A1 | Krieg et al. | 01-11-2007 |
| | | 2007-0010470 | A1 | Krieg et al. | 01-11-2007 |
| | | 2007-0037767 | A1 | Bratzler et al. | 02-15-2007 |

| | |
|-----------|------------------|
| EXAMINER: | DATE CONSIDERED: |
|-----------|------------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | | | |
|---|---|----|----|-----------------------------|--|-----------------------------------|--|
| FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICATION NO.: 10/627,331 | | ATTY. DOCKET NO.: C1039.70078US00 | |
| | | | | FILING DATE: July 25, 2003 | | CONFIRMATION NO.: 4362 | |
| | | | | APPLICANT: Krieg et al. | | | |
| | | | | GROUP ART UNIT: 1648 | | EXAMINER: Emily M. Le | |
| Sheet | 5 | of | 12 | | | | |

| | | | | | |
|--|--|--------------|----|-----------------|------------|
| | | 2007-0065467 | A1 | Krieg et al. | 03-22-2007 |
| | | 2007-0066553 | A1 | Krieg et al. | 03-22-2007 |
| | | 2007-0066554 | A1 | Krieg et al. | 03-22-2007 |
| | | 2007-0078104 | A1 | Krieg et al. | 04-05-2007 |
| | | 2007-0129320 | A9 | Davis et al. | 06-07-2007 |
| | | 2007-0142315 | A1 | Forsbach et al. | 06-21-2007 |
| | | 2007-0184465 | A1 | Wagner et al. | 08-09-2007 |
| | | 2007-0202128 | A1 | Krieg et al. | 08-30-2007 |
| | | 2007-0224210 | A1 | Krieg et al. | 09-27-2007 |
| | | 2007-0232622 | A1 | Lipford et al. | 10-04-2007 |

FOREIGN PATENT DOCUMENTS

| Examiner's Initials # | Cite No. | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Translation (Y/N) |
|--------------------------|-------------|-------------------------|-------------|--------------|--|---|----------------------|
| | | Office/ Country | Number | Kind Code | | | |
| | * | WO | 99/56755 | A1 | University of Iowa Research Foundation | 11-11-1999 | |
| | * | WO | 00/06588 | A1 | University of Iowa Research Foundation | 02-10-2000 | |
| | * | WO | 00/14217 | A2 | CPG Immunopharmaceuticals GMBH | 03-16-2000 | |
| | * | WO | 00/67023 | A1 | CPG Immunopharmaceuticals GMBH | 11-09-2000 | |
| | | WO | 03/002065 | A2 | Chiron Corporation | 01-09-2003 | |
| | * | WO | 2004/007743 | A2 | Coley Pharmaceutical GMBH | 01-22-2004 | |
| | * | WO | 2004/026888 | A2 | Coley Pharmaceutical GMBH | 04-01-2004 | |
| | * | WO | 2004/094671 | A2 | Coley Pharmaceutical GMBH | 11-04-2004 | |
| | | WO | 2005/004910 | A2 | Intercell Ag | 01-20-2005 | |
| | | WO | 2005/023289 | A1 | Intellectual Property Consulting Incorporated | 03-17-2005 | Y – Abs |
| | * | WO | 2006/080946 | A2 | Coley Pharmaceutical GMBH | 08-03-2006 | |
| | * | WO | 2007/031877 | A2 | Coley Pharmaceutical GMBH | 03-22-2007 | |
| | * | WO | 2007/038720 | A2 | Coley Pharmaceutical GMBH | 04-05-2007 | |

OTHER ART – NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials # | Cite No | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | Translation (Y/N) |
|--------------------------|------------|---|----------------------|
| | * | Press Release, January 2007, "Coley Pharmaceutical Group Updates Hepatitis C Drug Development Strategy". | |
| | * | Press Release, June 2007, "Coley Pharmaceutical Group Announces Pfizer's Discontinuation of Clinical Trials for PF-3512676 Combined with Cytotoxic Chemotherapy in Advanced Non Small Cell Lung Cancer". | |

| | |
|-----------|------------------|
| EXAMINER: | DATE CONSIDERED: |
|-----------|------------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | |
|---|---|----|----|-----------------------------|-----------------------------------|
| FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICATION NO.: 10/627,331 | ATTY. DOCKET NO.: C1039.70078US00 |
| | | | | FILING DATE: July 25, 2003 | CONFIRMATION NO.: 4362 |
| | | | | APPLICANT: Krieg et al. | |
| | | | | GROUP ART UNIT: 1648 | EXAMINER: Emily M. Le |
| Sheet | 6 | of | 12 | | |

| | |
|---|---|
| * | AGRAWAL et al., Medicinal chemistry and therapeutic potential of CpG DNA. Trends Mol Med. 2002 Mar;8(3):114-21. |
| * | BRANDA et al., B-cell proliferation and differentiation in common variable immunodeficiency patients produced by an antisense oligomer to the rev gene of HIV-1. Clin Immunol Immunopathol. 1996 May;79(2):115-21. |
| * | CHACE et al., Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. Clin Immunol Immunopathol. 1997 Aug;84(2):185-93. |
| * | COOPER et al., CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS. 2005 Sep 23;19(14):1473-9. |
| * | DAVIS et al., CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine. 2000 Mar 17;18(18):1920-4. |
| | DAVIS et al., CpG ODN is safe and highly effective in humans as adjuvant to HBV vaccine: Preliminary results of Phase I trial with CpG ODN 7909. Third Annual Conference on Vaccine Res. 2000. Abstract s25, number 47. |
| | FIELDS et al., Fields' Virology. 2001;1:1153. |
| | GRAMZINSKI et al., Immune response to a hepatitis B DNA vaccine in Aotus monkeys: a comparison of vaccine formulation, route, and method of administration. Mol Med. 1998 Feb;4(2):109-18. |
| * | HALPERIN et al., A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine. 2003 Jun 2;21(19-20):2461-7. |
| * | HSIEH et al., Incorporation of CpG oligodeoxynucleotide fails to enhance the protective efficacy of a subunit vaccine against Mycobacterium tuberculosis. Vaccine. 2004 Jan 26;22(5-6):655-9. |
| * | JACOBSON et al., Early viral response and on treatment response to CpG 10101 (ACTILON™), in combination with pegylated interferon and/or ribavirin, in chronic HCV genotype 1 infected patients with prior relapse response. 57 th Annual Meeting of American Association for the Study of the Liver Diseases (AASLD). 2006 Oct 30, Boston, Massachusetts; Presented Abstract #96. |
| | JIAO et al., Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomes. J Gen Virol. 2004 Jun;85(Pt 6):1545-53. |
| * | KATAOKA et al., Immunotherapeutic potential in guinea-pig tumor model of deoxyribonucleic acid from Mycobacterium bovis BCG complexed with poly-L-lysine and carboxymethylcellulose. Jpn J Med Sci Biol. 1990 Oct;43(5):171-82. |
| * | KOVARIK et al., CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J Immunol. 1999 Feb 1;162(3):1611-7. |
| * | KRIEG et al., Lymphocyte activation mediated by oligodeoxynucleotides or DNA containing novel un-methylated CpG motifs. American College of Rheumatology 58 th National Scientific Meeting. Minneapolis, Minnesota, October 22, 1994. Abstracts. Arthritis Rheum. 1994 Sep;37(9 Suppl). |
| * | KRIEG et al., Bacterial DNA or oligonucleotides containing CpG motifs protect mice from lethal L. monocytogenes challenge. 1996 Meeting on Molecular Approaches to the Control of Infectious Diseases. Cold Spring Harbor Laboratory, September 9-13, 1996:116. |
| * | KRIEG et al., Unmethylated CpG DNA protects mice from lethal listeria monocytogenes challenge. Vaccines. 1997; 97:77-9. |
| * | KRIEG et al., Infection. In: McGraw Hill Book. 1996:242-3. |

| | |
|-----------|------------------|
| EXAMINER: | DATE CONSIDERED: |
|-----------|------------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | | | |
|---|---|----|----|-----------------------------|--|-----------------------------------|--|
| FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICATION NO.: 10/627,331 | | ATTY. DOCKET NO.: C1039.70078US00 | |
| | | | | FILING DATE: July 25, 2003 | | CONFIRMATION NO.: 4362 | |
| | | | | APPLICANT: Krieg et al. | | | |
| | | | | GROUP ART UNIT: 1648 | | EXAMINER: Emily M. Le | |
| Sheet | 7 | of | 12 | | | | |

| | |
|---|--|
| * | KRIEG et al., Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. Trends Microbiol. 1996 Feb;4(2):73-6. |
| * | KRIEG et al., Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother. 2004 Nov-Dec;27(6):460-71. |
| * | KRIEG, Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006 Jun;5(6):471-84. |
| * | KULKARNI et al., Effect of dietary nucleotides on response to bacterial infections. JPEN J Parenter Enteral Nutr. 1986 Mar-Apr;10(2):169-71. |
| * | KURAMOTO et al., Induction of T-cell-mediated immunity against MethA fibrosarcoma by intratumoral injections of a bacillus Calmette-Guerin nucleic acid fraction. Cancer Immunol Immunother. 1992;34(5):283-8. |
| * | KURAMOTO et al., Changes of host cell infiltration into Meth A fibrosarcoma tumor during the course of regression induced by injections of a BCG nucleic acid fraction. Int J Immunopharmacol. 1992 Jul;14(5):773-82. |
| * | KURAMOTO et al., In situ infiltration of natural killer-like cells induced by intradermal injection of the nucleic acid fraction from BCG. Microbiol Immunol. 1989;33(11):929-40. |
| * | LIU et al., Recombinant interleukin-6 protects mice against experimental bacterial infection. Infect Immun. 1992 Oct;60(10):4402-6. |
| * | MA et al., DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice. Vaccine. 2002 Sep 10;20(27-28):3263-71. |
| * | MALANCHERE-BRES et al., CpG oligodeoxynucleotides with hepatitis B surface antigen (HbsAg) for vaccination in HbsAg-transgenic mice. J Virol. 2001 Jul;75(14):6482-91. |
| * | MANNS et al., Treating viral hepatitis C: Efficacy, side effects, and complications. Gut 2006 Sep;55(9):1350-9. |
| | McCLUSKIE et al., CpG DNA as mucosal adjuvant. Vaccine. 2000;18: 231-7. |
| * | McCLUSKIE et al., Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine. 2000 Oct 15;19(4-5):413-22. |
| * | McCLUSKIE et al., Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes. Viral Immunol. 1998;11(4):245-52. |
| * | McCLUSKIE et al., Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA. FEMS Immunol Med Microbiol. 2002 Feb 18;32(3):179-85. |
| * | McHUTCHISON et al., Early viral response to CpG 10101, in combination with pegylated interferon and/or ribavirin, in chronic HCV genotype 1 infected patients with prior relapse response. 41 st Annual Meeting of European Association for the Study of the Liver (EASL). 2006 April 26-30, Vienna, Austria; Submitted Abstract. |
| * | McHUTCHISON et al., Final results of a multi-center phase 1B, randomized, placebo-controlled, dose-escalation trial of CpG 10101 in patients with chronic hepatitis C virus. 41 st Annual Meeting of European Association for the Study of the Liver (EASL). 2006 April 30, Vienna, Austria; Presented Abstract #111. |

| | |
|-----------|------------------|
| EXAMINER: | DATE CONSIDERED: |
|-----------|------------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | |
|--|---|----|----|-----------------------------|-----------------------------------|
| FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICATION NO.: 10/627,331 | ATTY. DOCKET NO.: C1039.70078US00 |
| | | | | FILING DATE: July 25, 2003 | CONFIRMATION NO.: 4362 |
| | | | | APPLICANT: Krieg et al. | |
| | | | | GROUP ART UNIT: 1648 | EXAMINER: Emily M. Le |
| Sheet | 8 | of | 12 | | |

| | | | |
|--|---|--|--|
| | * | McHUTCHISON et al., Early clinical results with CpG 10101, a new investigational antiviral TLR9 agonist being developed for treatment of subjects chronically infected with hepatitis C virus. 12 th International Symposium on Viral Hepatitis and Liver Disease (ISVHLD). 2006 July 3, Paris, France; Presented Abstract #O105. | |
| | * | MESSINA et al., The influence of DNA structure on the in vitro stimulation of murine lymphocytes by natural and synthetic polynucleotide antigens. Cell Immunol. 1993 Mar;147(1):148-57. | |
| | * | RANKIN et al., CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev. 2001 Oct;11(5):333-40. | |
| | | RAZ et al., Potential role of immunostimulatory DNA sequences (ISS) in genetic immunization and autoimmunity. ACR Poster Session C: Cytokines and Inflammatory Mediators. 1996 Oct 20; Abstract 615. | |
| | * | SATOH et al., The study of mechanisms in CpG oligodeoxynucleotides-induced aggravation in murine allergic contact dermatitis to 2,4-dinitrofluorobenzene. Fukushima Igaku Zasshi. 2002;52(3):237-50. | |
| | * | SONEHARA et al., Hexamer palindromic oligonucleotides with 5'-CG-3' motif(s) induce production of interferon. J Interferon Cytokine Res. 1996 Oct;16(10):799-803. | |
| | * | STEIN et al., Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res Dev. 1994 Summer;4(2):67-9. | |
| | * | STEIN et al., Non-antisense effects of oligodeoxynucleotides. Antisense Technology. 1997; ch11: 241-64. | |
| | * | STEIN et al., Antisense oligonucleotides as therapeutic agents—is the bullet really magical? Science. 1993 Aug 20;261(5124):1004-12. | |
| | * | THREADGILL et al., Mitogenic synthetic polynucleotides suppress the antibody response to a bacterial polysaccharide. Vaccine. 1998 Jan;16(1):76-82. | |
| | * | VERTHELYI et al., CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques. AIDS. 2004 Apr 30;18(7):1003-8. | |
| | * | WAAG et al., Injection of inactivated phase I Coxiella burnetii increases non-specific resistance to infection and stimulates lymphokine production in mice. Ann N Y Acad Sci. 1990;590:203-14. | |
| | * | ZHAO et al., Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. Antisense Nucleic Acid Drug Dev. 1997 Oct;7(5):495-502. | |
| | * | Patent Interference No. 105,171. Iowa Preliminary Motion 3 (for judgment based on failure to comply with 35 U.S.C. 135(b)). (Electronically filed, unsigned). June 7, 2004. | |
| | * | Patent Interference No. 105,171. Iowa Preliminary Motion 4 (for judgment of no interference in fact). (Electronically filed, unsigned). June 7, 2004. | |
| | * | Patent Interference No. 105,171. Iowa Preliminary Motion 5 (for judgment based on lack of enablement). (Electronically filed, unsigned). June 7, 2004. | |
| | * | Patent Interference No. 105,171. Iowa Preliminary Motion 6 (for judgment based on lack of adequate written description). (Electronically filed, unsigned). June 7, 2004. | |
| | * | Patent Interference No. 105,171. Iowa Preliminary Motion 7 (motion to redefine interference to designate claims as not corresponding to the Count). (Electronically filed, unsigned). June 7, 2004. | |

| | |
|-----------|------------------|
| EXAMINER: | DATE CONSIDERED: |
|-----------|------------------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | | | |
|---|---|----|----|-----------------------------|--|-----------------------------------|--|
| FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICATION NO.: 10/627,331 | | ATTY. DOCKET NO.: C1039.70078US00 | |
| | | | | FILING DATE: July 25, 2003 | | CONFIRMATION NO.: 4362 | |
| | | | | APPLICANT: Krieg et al. | | | |
| | | | | GROUP ART UNIT: 1648 | | EXAMINER: Emily M. Le | |
| Sheet | 9 | of | 12 | | | | |

| | | | |
|--|---|--|--|
| | * | Patent Interference No. 105,171. Iowa Preliminary Motion 8 (contingent motion to redefine the Count). (Electronically filed, unsigned). June 7, 2004. | |
| | * | Patent Interference No. 105,171. Iowa Preliminary Motion 9 (motion for benefit of earlier application). (Electronically filed, unsigned). June 7, 2004. | |
| | * | Patent Interference No. 105,171. Iowa Preliminary Motion 10 (contingent motion to redefine the interference by adding a continuation application). (Electronically filed, unsigned). July 2, 2004. | |
| | * | Patent Interference No. 105,171. Regents of the University of California Opposition 3 (to Iowa Preliminary Motion 3 for judgment under 35 USC 135(b)). September 9, 2004. | |
| | * | Patent Interference No. 105,171. Regents of the University of California Opposition 4 (to Iowa Preliminary Motion 4 for judgment of no interference in fact). September 9, 2004. | |
| | * | Patent Interference No. 105,171. Regents of the University of California Opposition 5 (to Iowa Preliminary Motion 5 for judgment that UC's claim is not enabled). September 9, 2004. | |
| | * | Patent Interference No. 105,171. Regents of the University of California Opposition 6 (to Iowa Preliminary Motion 6 for judgment based on lack of adequate written description). September 9, 2004. | |
| | * | Patent Interference No. 105,171. Regents of the University of California Opposition 7 (to Iowa Preliminary Motion 7 to redefine the interference). September 9, 2004. | |
| | * | Patent Interference No. 105,171. Regents of the University of California Opposition 8 (to Iowa Preliminary Motion 8 to redefine the Count). September 9, 2004. | |
| | * | Patent Interference No. 105,171. Regents of the University of California Response 9 (to Iowa Contingent Motion 9 for benefit). September 9, 2004. | |
| | * | Patent Interference No. 105,171. Regents of the University of California Opposition 10 (to Iowa Contingent Motion 10 to redefine the interference). September 9, 2004. | |
| | * | Patent Interference No. 105,171. Regents of the University of California Opposition 11 (to Iowa Contingent Motion 11 to suppress). October 15, 2004. | |
| | * | Patent Interference No. 105,171. Iowa Reply 3 (in support of Iowa Preliminary Motion 3 for judgment under 35 U.S.C. §135(b)) (Electronically filed, unsigned). October 15, 2004. | |
| | * | Patent Interference No. 105,171. Iowa Reply 4 (in support of Iowa Preliminary Motion for judgment of no interference in fact) (Electronically filed, unsigned). October 15, 2004. | |
| | * | Patent Interference No. 105,171. Iowa Reply 5 (in support of Iowa Preliminary Motion 5 for judgment that UC's claim 205 is not enabled) (Electronically filed, unsigned). October 15, 2004. | |
| | * | Patent Interference No. 105,171. Iowa Reply 6 (in support of Iowa Preliminary Motion 6 for judgment based on lack of adequate written description) (Electronically filed, unsigned). October 15, 2004. | |
| | * | Patent Interference No. 105,171. Iowa Reply 7 (in support of Iowa Preliminary Motion 7 to redefine the interference) (Electronically filed, unsigned). October 15, 2004. | |
| | * | Patent Interference No. 105,171. Iowa Reply 8 (in support of Iowa Preliminary Motion 8 to redefine the count) (Electronically filed, unsigned). October 15, 2004. | |
| | * | Patent Interference No. 105,171. Iowa Reply 10 (in support of Iowa Preliminary Motion 10 to redefine the interference) (Electronically filed, unsigned). October 15, 2004. | |
| | * | Patent Interference No. 105,171. Iowa Reply 11 (in support of Iowa Miscellaneous Motion to suppress). (Electronically filed, unsigned). October 18, 2004. | |

| | |
|-----------|------------------|
| EXAMINER: | DATE CONSIDERED: |
|-----------|------------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | |
|---|----|----|----|-----------------------------|-----------------------------------|
| FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICATION NO.: 10/627,331 | ATTY. DOCKET NO.: C1039.70078US00 |
| | | | | FILING DATE: July 25, 2003 | CONFIRMATION NO.: 4362 |
| | | | | APPLICANT: Krieg et al. | |
| | | | | GROUP ART UNIT: 1648 | EXAMINER: Emily M. Le |
| Sheet | 10 | of | 12 | | |

| | | | |
|--|---|---|--|
| | * | Patent Interference No. 105,171. Regents of the University of California Preliminary Statement. June 7, 2004. | |
| | * | Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 1 (to designate additional claims of Iowa patent as corresponding to the Count). June 7, 2004. | |
| | * | Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 2 (for judgment based on lack of written description support and introducing new matter). June 7, 2004. | |
| | * | Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 3 (for judgment based on anticipation). June 7, 2004. | |
| | * | Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 4 (for judgment based on obviousness). June 7, 2004. | |
| | * | Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 5 (for judgment based on anticipation). June 7, 2004. | |
| | * | Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 6 (for judgment based on inequitable conduct). June 7, 2004. | |
| | * | Patent Interference No. 105,171. Regents of the University of California Contingent Preliminary Motion 7 (for benefit of an earlier application under 37 CFR 1.633(j)). July 2, 2004. | |
| | * | Patent Interference No. 105,171. Regents of the University of California Contingent Preliminary Motion 8 (to add additional claims under 37 CFR 1.633(c)(2) and (i)). July 2, 2004. | |
| | * | Amended Claims for Application Number 09/265,191, filed March 10, 1999. | |
| | * | Patent Interference No. 105,171. Iowa Opposition 1 (opposition to motion to designate additional claims as corresponding to the Count) (Electronically filed, unsigned). September 9, 2004. | |
| | * | Patent Interference No. 105,171. Iowa Opposition 2 (opposition to motion for judgment based on lack of written description support and introducing new matter) (Electronically filed, unsigned). September 9, 2004. | |
| | * | Patent Interference No. 105,171. Iowa Opposition 3 (opposition to motion for judgment based on anticipation) (Electronically filed, unsigned). September 9, 2004. | |
| | * | Patent Interference No. 105,171. Iowa Opposition 4 (opposition to motion for judgment based on obviousness) (Electronically filed, unsigned). September 9, 2004. | |
| | * | Patent Interference No. 105,171. Iowa Opposition 5 (opposition to motion for judgment based on anticipation) (Electronically filed, unsigned). September 9, 2004. | |
| | * | Patent Interference No. 105,171. Iowa Opposition 6 (opposition to motion for judgment based on inequitable conduct) (Electronically filed, unsigned). September 9, 2004. | |
| | * | Patent Interference No. 105,171. Iowa Opposition 7 (opposition to motion for benefit of an earlier application under 7 CFR 1.633(j)) (Electronically filed, unsigned). September 9, 2004. | |
| | * | Patent Interference No. 105,171. Iowa Opposition 8 (opposition to motion to add additional claims under 37 CFR 1.633 (2) and (i)) (Electronically filed, unsigned). September 9, 2004. | |
| | * | Patent Interference No. 105,171. Regents of the University of California Reply 1 (to Iowa's opposition to UC's motion to designate Iowa claims as corresponding to the Count). October 15, 2004. | |
| | * | Patent Interference No. 105,171. Regents of the University of California Reply 2 (to Iowa's opposition to UC Preliminary Motion 2 for Judgment). October 15, 2004. | |
| | * | Patent Interference No. 105,171. Regents of the University of California Reply 3 (to Iowa's Opposition to UC Preliminary Motion 3 for Judgment). October 15, 2004. | |

| | |
|-----------|------------------|
| EXAMINER: | DATE CONSIDERED: |
|-----------|------------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | | | |
|---|----|----|----|-----------------------------|--|-----------------------------------|--|
| FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICATION NO.: 10/627,331 | | ATTY. DOCKET NO.: C1039.70078US00 | |
| | | | | FILING DATE: July 25, 2003 | | CONFIRMATION NO.: 4362 | |
| | | | | APPLICANT: Krieg et al. | | | |
| | | | | GROUP ART UNIT: 1648 | | EXAMINER: Emily M. Le | |
| Sheet | 11 | of | 12 | | | | |

| | | | |
|--|---|---|--|
| | * | Patent Interference No. 105,171. Regents of the University of California Reply 4 (to Iowa's Opposition to UC Preliminary Motion 4 for Judgment). October 15, 2004. | |
| | * | Patent Interference No. 105,171. Regents of the University of California Reply 5 (to Iowa's Opposition to UC Preliminary Motion 5 for Judgment). October 15, 2004. | |
| | * | Patent Interference No. 105,171. Regents of the University of California Reply 6 (to Iowa's opposition to UC Preliminary Motion 6 for judgment). October 15, 2004. | |
| | * | Patent Interference No. 105,171. Regents of the University of California Reply 7 (to Iowa's Opposition to UC Preliminary Motion 7 for Benefit). October 15, 2004. | |
| | * | Patent Interference No. 105,171. Regents of the University of California Reply 8 (to Iowa's Opposition to UC Preliminary Motion 8 to add additional claims). October 15, 2004. | |
| | * | Patent Interference No. 105,171. Decision on Motion under 37 CFR §41.125. March 10, 2005. | |
| | * | Patent Interference No. 105,171. Judgment and Order. March 10, 2005. | |
| | * | Patent Interference No. 105,171. Regents of the University of California. Brief of Appellant. July 5, 2005. | |
| | * | Patent Interference No. 105,171. University of Iowa and Coley Pharmaceutical Group, Inc. Brief of Appellees. August 17, 2005. | |
| | * | Patent Interference No. 105,171. Regents of the University of California. Reply Brief of Appellant. September 6, 2005. | |
| | * | Patent Interference No. 105,171. Regents of the University of California. Decision of CAFC. July 17, 2006. | |
| | * | Patent Interference No. 105,526. Krieg Substantive Motion 1 (for unpatentability based on interference estoppel). (Electronically filed, unsigned). | |
| | * | Patent Interference No. 105,526.. Krieg Substantive Motion 2 (for judgment based on inadequate written description and/or enablement). (Electronically filed, unsigned). June 18, 2007. | |
| | * | Patent Interference No. 105,526. Krieg Contingent Responsive Motion (to add new claims 104 and 105). (Electronically filed, unsigned). July 25, 2007. | |
| | * | Patent Interference No. 105,526. Krieg Substantive Motion 3 (for judgment based on prior art). (Electronically filed, unsigned). June 18, 2007. | |
| | * | Patent Interference No. 105,526. Raz Motion 1 (Unpatentability of Krieg Claims under 35 U.S.C. § 112, First Paragraph). (Electronically filed, unsigned). June 18, 2007. | |
| | * | Patent Interference No. 105,526. Raz Motion 2 (Raising a Threshold Issue of No Interference-in-Fact). (Electronically filed, unsigned). June 18, 2007. | |
| | * | Patent Interference No. 105,526.. Raz Motion 3 (Krieg's Claims are Unpatentable Over Prior Art Under 35 U.S.C. § 102(b)) (Electronically filed, unsigned). June 18, 2007. | |
| | * | Patent Interference No. 105,526. Raz Motion 4 (To Designate Krieg Claims 46 and 82-84 as Corresponding to Count 1). (Electronically filed, unsigned). June 18, 2007. | |
| | * | Patent Interference No. 105,526. Raz Responsive Miscellaneous Motion 5 (To revive the Raz Parent Application) (Electronically filed, unsigned) July 25, 2007. | |
| | * | Patent Interference No. 105,526. Raz Contingent Responsive Motion 6 (To Add a New Claim 58) (Electronically filed, unsigned) July 25, 2007. | |
| | * | Patent Interference No. 105,526. Krieg Opposition 1 (Opposition to Motion for Lack of Enablement and Written Description) (Electronically filed, unsigned) September 10, 2007. | |

| | |
|-----------|------------------|
| EXAMINER: | DATE CONSIDERED: |
|-----------|------------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | | | |
|---|----|----|----|-----------------------------|--|-----------------------------------|--|
| FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICATION NO.: 10/627,331 | | ATTY. DOCKET NO.: C1039.70078US00 | |
| | | | | FILING DATE: July 25, 2003 | | CONFIRMATION NO.: 4362 | |
| | | | | APPLICANT: Krieg et al. | | | |
| | | | | GROUP ART UNIT: 1648 | | EXAMINER: Emily M. Le | |
| Sheet | 12 | of | 12 | | | | |

| | | | |
|--|---|---|--|
| | * | Patent Interference No. 105,526. Krieg Opposition 2 (to Raz Motion 2) (Electronically filed, unsigned) September 10, 2007. | |
| | * | Patent Interference No. 105,526. Krieg Opposition 3 (To Raz Motion 3) (Electronically filed, unsigned) September 10, 2007. | |
| | * | Patent Interference No. 105,526. Krieg Opposition 4 (Opposition to Motion for Designating Claims 46 and 82-84 as Corresponding to the Court) (Electronically filed, unsigned) September 10, 2007. | |
| | * | Patent Interference No. 105,526. Krieg Opposition 6 (Opposition to Raz Contingent Responsive Motion 6) (Electronically filed, unsigned) September 10, 2007. | |
| | * | Patent Interference No. 105,526. Raz Opposition 1 (Opposing Krieg Substantive Motion 1) (Electronically filed, unsigned) September 10, 2007. | |
| | * | Patent Interference No. 105,526. Raz Opposition 2 (Opposing Krieg Substantive Motion 2) (Electronically filed, unsigned) September 10, 2007. | |
| | * | Patent Interference No. 105,526. Raz Opposition 4 (Opposing Krieg Contingent Responsive Motion to Add New Claims 104 and 105) (Electronically filed, unsigned) September 10, 2007. | |
| | * | Patent Interference No. 105,526. Krieg Reply 1 (Reply to Raz opposition 1) October 5, 2007 | |
| | * | Patent Interference No. 105,526. Krieg Reply 2 (Reply to Raz opposition 2) October 5, 2007 | |
| | * | Patent Interference No. 105,526. Krieg Reply 4 (Reply to Raz opposition 4) October 5, 2007 | |
| | * | Patent Interference No. 105,526. Raz Reply 1 (Reply to Krieg opposition 1) October 5, 2007 | |
| | * | Patent Interference No. 105,526. Raz Reply 2 (Reply to Krieg opposition 2) October 5, 2007 | |
| | * | Patent Interference No. 105,526. Raz Reply 3 (Reply to Krieg opposition 3) October 5, 2007 | |
| | * | Patent Interference No. 105,526. Raz Reply 4 (Reply to Krieg opposition 4) October 5, 2007 | |
| | * | Patent Interference No. 105,526. Raz Reply 6 (Reply to Krieg opposition 6) October 5, 2007 | |
| | * | Patent Interference No. 105,526. Krieg Miscellaneous Motion 5 (To exclude exhibits 2066, 2070, 2071, 2072, 2073, 2074, 2075, 2076 and 2078) October 9, 2007. | |
| | * | Patent Interference No. 105,526. Raz Opposition 5 (Opposing Krieg Miscellaneous Motion 5) October 25, 2007. | |
| | * | Patent Interference No. 105,526. Raz Miscellaneous Motion 7 (To exclude evidence) October 19, 2007. | |
| | * | Patent Interference No. 105,526. Krieg Opposition 7 (To Raz Miscellaneous Motion 7) October 25, 2007. | |
| | * | Patent Interference No. 105,526. Krieg Reply 5 (Reply to Raz opposition 5) October 30, 2007. | |
| | * | Patent Interference No. 105,526. Raz Reply 7 (Reply to Krieg opposition 7) October 30, 2007. | |

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/630,319, filed July 31, 2000 and/or 10/187,489, filed July 2, 2002, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

| | |
|-----------|------------------|
| EXAMINER: | DATE CONSIDERED: |
|-----------|------------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.